Drug Profile
Research programme: neglected parasitic disease therapeutics - MMV/DNDi/Evotec SE
Alternative Names: Chaga's disease therapeutics - DNDi/MMV; Leishmaniasis therapeutics - DNDi/MMV; Therapeutics for neglected tropical diseases (NTDs) - Drugs for Neglected Diseases initiative/Medicines for Malaria Venture; Trypanosomiasis therapeutics - DNDi/MMVLatest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Medicines for Malaria Venture
- Developer Drugs for Neglected Diseases Initiative Foundation; Evotec SE; Medicines for Malaria Venture
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Falciparum malaria; Filariasis; Leishmaniasis
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Falciparum-malaria in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Belgium
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Switzerland